NasdaqCM:MBOT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	6	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
9/30/2024	N/A	-11	-9	-9	N/A
6/30/2024	N/A	-10	-8	-8	N/A
3/31/2024	N/A	-10	-8	-8	N/A
12/31/2023	N/A	-11	-9	-9	N/A
9/30/2023	N/A	-11	-9	-9	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-13	-12	-12	N/A
12/31/2022	N/A	-13	-12	-12	N/A
9/30/2022	N/A	-14	-12	-12	N/A
6/30/2022	N/A	-13	-11	-11	N/A
3/31/2022	N/A	-12	-10	-10	N/A
12/31/2021	N/A	-11	-9	-9	N/A
9/30/2021	N/A	-10	-8	-8	N/A
6/30/2021	N/A	-10	-8	-8	N/A
3/31/2021	N/A	-9	-7	-7	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-8	-8	-7	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-7	-6	-6	N/A
12/31/2019	N/A	-7	-7	-6	N/A
9/30/2019	N/A	-8	-6	-6	N/A
6/30/2019	N/A	-7	-6	-6	N/A
3/31/2019	N/A	-8	-7	-7	N/A
12/31/2018	N/A	-7	-6	-5	N/A
9/30/2018	N/A	-7	-5	-5	N/A
6/30/2018	N/A	-6	N/A	-5	N/A
3/31/2018	N/A	-8	N/A	-5	N/A
12/31/2017	N/A	-8	N/A	-5	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-14	N/A	-3	N/A
3/31/2017	N/A	-11	N/A	-1	N/A
12/31/2016	N/A	-10	N/A	-1	N/A
9/30/2016	N/A	-2	N/A	-1	N/A
6/30/2016	N/A	-1	N/A	-1	N/A
3/31/2016	N/A	-1	N/A	-1	N/A
12/31/2015	N/A	-1	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van MBOT boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van MBOT naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van MBOT naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van MBOT ( 256.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van MBOT ( 256.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MBOT naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/02/09 02:16
Aandelenkoers aan het einde van de dag	2025/02/07 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Microbot Medical Inc. wordt gevolgd door 2 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Raghuram Selvaraju	H.C. Wainwright & Co.
Jeffrey Cohen	Ladenburg Thalmann & Company

Microbot Medical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 60% to US$8.00

Price target decreased by 58% to US$8.00

Recent updates

Insufficient new directors

Microbot Medical Inc. Appoints Ms. Michal Ahuvia to the Newly Created Role of Director of Operations

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $8.600009 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $7.000002 million.

New major risk - Share price stability

Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY

Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New minor risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Price target decreased by 60% to US$8.00

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Price target decreased by 58% to US$8.00

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical acquires Nitiloop, terms undisclosed

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical confirms GLP trial on track to begin later this month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022

High number of new directors

Will Microbot Medical (NASDAQ:MBOT) Spend Its Cash Wisely?

High number of new directors

Microbot Medical Inc. Announces Executive Changes

Microbot Medical's Stryker Collaboration Makes This An Intriguing High Flier